MedTrace Logo

Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)

NCT00478114 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-08-29

No results posted yet for this study

Summary

This is the early access programme (EAP) of sorafenib in the indication of advanced renal cell carcinoma (RCC). The study is to evaluate the efficacy and safety of sorafenib in patients with advanced RCC.

Conditions

Interventions

DRUG

sorafenib

sorafenib in the patients with advanced Renal Cell Carcinoma

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Mahidol University

    lead OTHER

Principal Investigators

  • Vichien Srimuninnimit, Ass.Prof. · Siriraj Hospital, Bangkok, Thailand

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-08-31
Completion
2010-03-31

Countries

  • Thailand

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478114 on ClinicalTrials.gov